ELI LILLY & Co (LLY) operating KPIs
LLYNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 20/3026% above fair value
$1417.54+43.84 (+3.19%)
Close on Oct 30, 2026Market cap $1.33TP/E 46.0Yield 0.44%
Latest, Q2 2026
14,413
Period ended Jun 30, 2026
Change on a year earlier
+33.3%
10,814 in Q2 2025
History
38 quarters
Since Q1 2017
Sources
33
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Geographic revenue — United States ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 14,413 | +33.3% | Form 10-Q (filed 2026-08-05) ↗ |
| Q1 2026 | Mar 31, 2026 | 12,119 | +42.8% | Form 10-Q (filed 2026-04-30) ↗ |
| Q4 2025 | Dec 31, 2025 | 12,877 | +42.6% | Form 10-K (filed 2026-02-12) ↗ |
| Q3 2025 | Sep 30, 2025 | 11,300 | +44.6% | Form 10-Q (filed 2025-10-30) ↗ |
| Q2 2025 | Jun 30, 2025 | 10,814 | +38.0% | Form 10-Q (filed 2026-08-05) ↗ |
| Q1 2025 | Mar 31, 2025 | 8,489 | +49.1% | Form 10-Q (filed 2026-04-30) ↗ |
| Q4 2024 | Dec 31, 2024 | 9,032 | +39.9% | Form 10-K (filed 2026-02-12) ↗ |
| Q3 2024 | Sep 30, 2024 | 7,814 | +45.6% | Form 10-Q (filed 2025-10-30) ↗ |
| Q2 2024 | Jun 30, 2024 | 7,835 | +41.6% | Form 10-Q (filed 2025-08-07) ↗ |
| Q1 2024 | Mar 31, 2024 | 5,694 | +28.4% | Form 10-Q (filed 2025-05-01) ↗ |
| Q4 2023 | Dec 31, 2023 | 6,455 | +38.6% | Form 10-K (filed 2026-02-12) ↗ |
| Q3 2023 | Sep 30, 2023 | 5,368 | +21.4% | Form 10-Q (filed 2024-10-30) ↗ |
| Q2 2023 | Jun 30, 2023 | 5,531 | +40.6% | Form 10-Q (filed 2024-08-08) ↗ |
| Q1 2023 | Mar 31, 2023 | 4,436 | -14.3% | Form 10-Q (filed 2024-04-30) ↗ |
| Q4 2022 | Dec 31, 2022 | 4,659 | -10.0% | Form 10-K (filed 2025-02-19) ↗ |
| Q3 2022 | Sep 30, 2022 | 4,422 | +10.8% | Form 10-Q (filed 2023-11-02) ↗ |
| Q2 2022 | Jun 30, 2022 | 3,935 | +6.2% | Form 10-Q (filed 2023-08-08) ↗ |
| Q1 2022 | Mar 31, 2022 | 5,175 | +31.3% | Form 10-Q (filed 2023-04-27) ↗ |
| Q4 2021 | Dec 31, 2021 | 5,176 | +12.6% | Form 10-K (filed 2024-02-21) ↗ |
| Q3 2021 | Sep 30, 2021 | 3,990 | +26.2% | Form 10-Q (filed 2022-11-01) ↗ |
| Q2 2021 | Jun 30, 2021 | 3,704 | +17.8% | Form 10-Q (filed 2022-08-04) ↗ |
| Q1 2021 | Mar 31, 2021 | 3,941 | +18.4% | Form 10-Q (filed 2022-04-29) ↗ |
| Q4 2020 | Dec 31, 2020 | 4,598 | +30.7% | Form 10-K (filed 2023-02-22) ↗ |
| Q3 2020 | Sep 30, 2020 | 3,161 | +3.3% | Form 10-Q (filed 2021-10-27) ↗ |
| Q2 2020 | Jun 30, 2020 | 3,145 | -3.3% | Form 10-Q (filed 2021-08-03) ↗ |
| Q1 2020 | Mar 31, 2020 | 3,329 | +15.2% | Form 10-Q (filed 2021-04-30) ↗ |
| Q4 2019 | Dec 31, 2019 | 3,519 | +7.2% | Form 10-K (filed 2022-02-23) ↗ |
| Q3 2019 | Sep 30, 2019 | 3,060 | -0.3% | Form 10-Q (filed 2020-10-28) ↗ |
| Q2 2019 | Jun 30, 2019 | 3,253 | +0.3% | Form 10-Q (filed 2020-07-31) ↗ |
| Q1 2019 | Mar 31, 2019 | 2,891 | +3.4% | Form 10-Q (filed 2020-05-01) ↗ |
| Q4 2018 | Dec 31, 2018 | 3,283 | +1.8% | Form 10-K (filed 2021-02-17) ↗ |
| Q3 2018 | Sep 30, 2018 | 3,071 | +11.6% | Form 10-Q (filed 2019-10-25) ↗ |
| Q2 2018 | Jun 30, 2018 | 3,242 | +11.1% | Form 10-Q (filed 2019-08-02) ↗ |
| Q1 2018 | Mar 31, 2018 | 2,796 | -4.7% | Form 10-Q (filed 2019-05-02) ↗ |
| Q4 2017 | Dec 31, 2017 | 3,226 | – | Form 10-K (filed 2020-02-19) ↗ |
| Q3 2017 | Sep 30, 2017 | 2,751 | – | Form 10-Q (filed 2018-11-06) ↗ |
| Q2 2017 | Jun 30, 2017 | 2,917 | – | Form 10-Q (filed 2018-07-25) ↗ |
| Q1 2017 | Mar 31, 2017 | 2,934 | – | Form 10-Q (filed 2018-04-27) ↗ |
Cite this data
StockData. (2026). Eli Lilly Geographic revenue — United States ($M) ($M), quarterly Q1 2017–Q2 2026 [Data set]. Compiled from Eli Lilly SEC filings and investor materials. https://stockdatahq.com/stocks/lly/kpis/rev_geo_us
See every metric in the Eli Lilly KPI table. Data updated Oct 25, 2026.